343 related articles for article (PubMed ID: 27939989)
1. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.
Chen L; Sung SS; Yip ML; Lawrence HR; Ren Y; Guida WC; Sebti SM; Lawrence NJ; Wu J
Mol Pharmacol; 2006 Aug; 70(2):562-70. PubMed ID: 16717135
[TBL] [Abstract][Full Text] [Related]
4. Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition.
Sampaio C; Dance M; Montagner A; Edouard T; Malet N; Perret B; Yart A; Salles JP; Raynal P
Mol Cell Biol; 2008 Jan; 28(2):587-600. PubMed ID: 18025104
[TBL] [Abstract][Full Text] [Related]
5. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor.
Yart A; Laffargue M; Mayeux P; Chretien S; Peres C; Tonks N; Roche S; Payrastre B; Chap H; Raynal P
J Biol Chem; 2001 Mar; 276(12):8856-64. PubMed ID: 11134009
[TBL] [Abstract][Full Text] [Related]
6. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor.
Ren Y; Meng S; Mei L; Zhao ZJ; Jove R; Wu J
J Biol Chem; 2004 Feb; 279(9):8497-505. PubMed ID: 14665621
[TBL] [Abstract][Full Text] [Related]
7. SHP2 is a target of the immunosuppressant tautomycetin.
Liu S; Yu Z; Yu X; Huang SX; Luo Y; Wu L; Shen W; Yang Z; Wang L; Gunawan AM; Chan RJ; Shen B; Zhang ZY
Chem Biol; 2011 Jan; 18(1):101-10. PubMed ID: 21276943
[TBL] [Abstract][Full Text] [Related]
8. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
9. The multi-site docking protein Grb2-associated binder 1 (Gab1) enhances interleukin-6-induced MAPK-pathway activation in an SHP2-, Grb2-, and time-dependent manner.
Bongartz H; Gille K; Hessenkemper W; Mandel K; Lewitzky M; Feller SM; Schaper F
Cell Commun Signal; 2019 Oct; 17(1):135. PubMed ID: 31651330
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
[TBL] [Abstract][Full Text] [Related]
11. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor.
Meng S; Chen Z; Munoz-Antonia T; Wu J
Biochem J; 2005 Oct; 391(Pt 1):143-51. PubMed ID: 15952937
[TBL] [Abstract][Full Text] [Related]
12. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
14. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2.
Zhang SQ; Tsiaras WG; Araki T; Wen G; Minichiello L; Klein R; Neel BG
Mol Cell Biol; 2002 Jun; 22(12):4062-72. PubMed ID: 12024020
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2.
Cunnick JM; Meng S; Ren Y; Desponts C; Wang HG; Djeu JY; Wu J
J Biol Chem; 2002 Mar; 277(11):9498-504. PubMed ID: 11779868
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
[TBL] [Abstract][Full Text] [Related]
17. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
18. Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.
Fukumoto T; Kubota Y; Kitanaka A; Yamaoka G; Ohara-Waki F; Imataki O; Ohnishi H; Ishida T; Tanaka T
Cell Signal; 2009 Dec; 21(12):1775-83. PubMed ID: 19665053
[TBL] [Abstract][Full Text] [Related]
19. A role for Grb2-associated binder-1 in growth hormone signaling.
Kim SO; Loesch K; Wang X; Jiang J; Mei L; Cunnick JM; Wu J; Frank SJ
Endocrinology; 2002 Dec; 143(12):4856-67. PubMed ID: 12446613
[TBL] [Abstract][Full Text] [Related]
20. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
